Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$MACK {{ '2016-10-03T16:20:06+0000' | timeago}} • Announcement

$MACK said it reduced 22% of its headcount while eliminating more than $200MM in expected costs over the next 2 years. The company also said its CEO Robert Mulroy resigned, effective immediately. The BoD appointed Chairman Gary Crocker as interim CEO. $MACK had reported a 2Q16 loss of $50.8MM, hurt by higher R&D costs and interest expenses.

$MYL {{ '2018-05-11T18:10:45+0000' | timeago}} • Infographic

$MYL Mylan N.V. Earnings AlphaGraphic: Q1 2018 Highlights

$CELG {{ '2018-05-11T16:57:57+0000' | timeago}} • Infographic

$CELG Celgene Corp. Earnings AlphaGraphic: Q1 2018 Highlights

$AGN {{ '2018-05-11T13:13:56+0000' | timeago}} • Infographic

$AGN Allergan Plc Earnings AlphaGraphic: Q1 2018 Highlights

$AGN {{ '2018-02-06T21:23:10+0000' | timeago}} • Infographic

$AGN Allergan Plc Earnings AlphaGraphic: Q4 2017 Highlights

$AGN {{ '2018-02-06T17:23:26+0000' | timeago}} • Announcement

For FY18, $AGN expects its total net revenues to be in the range of $15.0 -15.3Bil and net loss per share is expected to be about $2.27-1.52. The company expects its 1Q18 total net revenues to be about $3.5-3.6Bil and net loss per share of about $1.27-1.07.

$AGN {{ '2018-02-06T17:17:53+0000' | timeago}} • Announcement

Drugmaker $AGN reported a profit for 4Q17 on strong demand for Botox. Net earnings came to $3.05Bil, or $8.88 per share, compared with a  year-earlier loss of $70.2MM, or $0.20 loss per share. Adj. EPS was $4.86. Revenue rose 12% YoY to $4.33Bil, helped by the sales growth in drugs like Botox, Alloderm and Juvederm collection.

$VRTX {{ '2018-02-01T22:20:21+0000' | timeago}} • Infographic

$VRTX Vertex Pharmaceuticals Earnings AlphaGraphic: Q4 2017 Highlights

$AGN {{ '2018-02-01T13:45:14+0000' | timeago}} • Announcement

$AGN agreed to pay $700MM to $TEVA to settle their working capital dispute arbitration. Teva expects to receive this payment from Allergan in 1Q18 and use this amount for repaying a portion of its term loan debt. As of Jan. 12, 2018, Allergan owns 6.8% of Teva shares.

$CELG {{ '2018-01-25T22:56:51+0000' | timeago}} • Announcement

$CELG, which made two multi-billion dollar buyouts (Impact & $JUNO) in the beginning of 2018, swung to a loss in 4Q17, hit by the income tax charges. Celgene reported a loss of $81MM or $0.10 per share on a GAAP basis compared to a profit of $429MM or $0.53 per share, hurt by the impact of Tax Cuts and Jobs Act. Adjusted EPS rose 24% to $2.00.

$CELG {{ '2018-01-25T14:18:11+0000' | timeago}} • Infographic

$CELG Celgene Corp. Earnings AlphaGraphic: Q4 2017 Highlights. The increase in Revlimid and Otezla drug sales helped to boost Celgene's total revenue by 17% to $3.483Bil in the fourth quarter of 2017. Celgene swung to loss in the recently ended quarter on the impact of 2017 Tax Act.

$CELG {{ '2018-01-22T13:26:32+0000' | timeago}} • Announcement

Last week's rumor becomes reality. $CELG to acquire its strategic partner $JUNO for $9Bil. Juno Therapeutics, which had already skyrocketed nearly 50% in the last week, has increased more than 25% today in pre-market from Jan. 19th closing price of $67.81. Celgene expects that this deal will help it to boost the revenue generation beyond 2020.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$VRTX {{ '2018-01-10T15:15:09+0000' | timeago}} • Announcement

$VRTX said the European Commission has granted extension of the Marketing Authorization for ORKAMBI, intended for the treatment of cystic fibrosis (CF) in people with two copies of the F508del mutation, to include children ages 6 through 11. Existing reimbursement agreements in countries such as Ireland will enable rapid access to ORKAMBI.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$MYL {{ '2017-12-29T16:32:47+0000' | timeago}} • Announcement

$MYL announced the U.S.launch of Estradiol Vaginal Cream, the first generic version of Allergan's Estrace Cream. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in the treatment of vulvar and vaginal atrophy.

$MYL {{ '2017-12-29T10:49:56+0000' | timeago}} • Announcement

$MYL said the biosimilar Trastuzumab, co-developed by the company and Biocon Ltd. has been approved by ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica. Trastuzumab is indicated for the treatment of breast cancer and gastric cancer. Libbs will commercialize the product in Brazil under the brand name Zedora.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

Recent Transcripts
PTN | Earnings
May 15th 2018, 3:00pm
MYL | Earnings
May 9th 2018, 2:00pm
TRXC | Earnings
May 8th 2018, 8:30pm
SYN | Earnings
May 8th 2018, 8:30pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
PTN | Earnings
May 15th 2018, 3:00pm
MYL | Earnings
May 9th 2018, 2:00pm
TRXC | Earnings
May 8th 2018, 8:30pm
SYN | Earnings
May 8th 2018, 8:30pm
AlphaGraphics you may like